C-terminal Mutations of the Immune Regulator Factor H as Described in Patients with Atypical Haemolytic Uraemic Syndrome Show Reduced Ligand Interaction and Endothelial Cell Binding.
Mihály Józsi(Eötvös Loránd University), Christine Skerka(OncoMed (United States)), Clemens W. Ostrowicz(Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI)), Andrea Hartmann(Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI)), Steffi Hälbich(Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI)), Christoph Licht(University of Toronto), R W Saunders, Zipfel Pf, Heiko Richter(Max Planck Institute for Innovation and Competition), Anja Kunert(Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI)), SJ Perkins, Stefan Heinen(Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI))
UCL Discovery (University College London)
January 1, 2006
Cited by 0
Related Papers
Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test
|Genetics in Medicine|2017|563
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
|Kidney International|2011|361
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency
|Blood|2007|356
Deletion of Complement Factor H–Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome
|PLoS Genetics|2007|325
Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)
|Kidney International|2006|203